- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Damora Therapeutics Inc (DMRA)
Damora Therapeutics Inc stock price live, this page displays NASDAQ DMRA stock exchange data. View the DMRA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Damora Therapeutics Inc real time stock price chart below.
What Is the Damora Therapeutics Inc Stock Price Today?
The Damora Therapeutics Inc stock price today is 30.680.
What Is the Stock Symbol for Damora Therapeutics Inc?
The stock symbol for Damora Therapeutics Inc is "DMRA."
What Stock Exchange Does Damora Therapeutics Inc Trade On?
Damora Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Damora Therapeutics Inc a Good Stock to Buy?
Determining whether Damora Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DMRA quote. (ISIN: KYG2646Y1044)
What Is the Damora Therapeutics Inc Stock Price Today?
The Damora Therapeutics Inc stock price today is 30.680.
What Is the Stock Symbol for Damora Therapeutics Inc?
The stock symbol for Damora Therapeutics Inc is "DMRA."
What Stock Exchange Does Damora Therapeutics Inc Trade On?
Damora Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Damora Therapeutics Inc a Good Stock to Buy?
Determining whether Damora Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DMRA quote. (ISIN: KYG2646Y1044)
30.680
-0.050(-0.16%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
29.500
30.750
52 wk Range
2.450
38.325
DMRA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
29.50030.750
52 wk Range
2.45038.325
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DMRA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
44.667
Upside
+45.59%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Analyst Ratings
10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 44.667
(+45.59% Upside)
Earnings
Latest Release
Aug 10, 2026
EPS / Forecast
-0.39 / -0.44
Revenue / Forecast
-- / --
Compare DMRA to Peers and Sector
Metrics to compare | DMRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDMRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.8x | −5.0x | −0.4x | |
PEG Ratio | −0.33 | 0.04 | 0.00 | |
Price/Book | 4.9x | 1.8x | 2.6x | |
Price / LTM Sales | - | 2.5x | 3.1x | |
Upside (Analyst Target) | 46.4% | 239.0% | 48.4% | |
Fair Value Upside | Unlock | −2.5% | 6.5% | Unlock |
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Damora Therapeutics (DMRA) Stock Price Today?
The Damora Therapeutics stock price today is 30.680 USD.
What Stock Exchange Does Damora Therapeutics Trade On?
Damora Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Damora Therapeutics?
The stock symbol for Damora Therapeutics is "DMRA."
What Is the Damora Therapeutics Market Cap?
As of today, Damora Therapeutics market cap is 1.890B USD.
What Is Damora Therapeutics's Earnings Per Share (TTM)?
The Damora Therapeutics EPS (TTM) is -9.876.
When Is the Next Damora Therapeutics Earnings Date?
Damora Therapeutics will release its next earnings report on Oct 30, 2026.
From a Technical Analysis Perspective, Is DMRA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Damora Therapeutics Stock Split?
Damora Therapeutics has split 1 times.
How Many Employees Does Damora Therapeutics Have?
Damora Therapeutics has 7 employees.
What is the current trading status of Damora Therapeutics (DMRA)?
As of Aug 14, 2026, Damora Therapeutics (DMRA) is trading at a price of 30.680 USD, with a previous close of 30.730 USD. The stock has fluctuated within a day range of 29.500 USD to 30.750 USD, while its 52-week range spans from 2.450 USD to 38.325 USD.
What Is Damora Therapeutics (DMRA) Price Target According to Analysts?
The average 12-month price target for Damora Therapeutics is 44.667 USD, with a high estimate of 51 USD and a low estimate of 40 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +45.59% Upside potential.
What Is the DMRA Premarket Price?
DMRA's last pre-market stock price is 30.320 USD. The pre-market share volume is 537.000, and the stock has decreased by -0.410, or -1.330%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.